InsiderTrades.com logo
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits   |   Ad
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
>> Register for the Workshop Now
Daniel P. Van Plew net worth and biography
  • Phone
  • Email
  • Website

Daniel Van Plew Biography and Net Worth

EVP of Regeneron Pharmaceuticals
Daniel Van Plew joined Regeneron in 2007 and has served as Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. From 2006 to 2007, he served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V., a global biopharmaceutical company. Between 2004 and 2006, Mr. Van Plew held positions of increasing responsibility at Chiron Biopharmaceuticals, most recently as Senior Director, Vacaville Operations. From 1998 until 2004, he held various managerial positions in the health and life sciences practice at Accenture, Ltd., a management consulting business. Mr. Van Plew received his MS in Chemistry from Penn State University and his MBA from Michigan State University.

What is Daniel P. Van Plew's net worth?

The estimated net worth of Daniel P. Van Plew is at least $15.92 million as of August 24th, 2023. Mr. Van Plew owns 21,508 shares of Regeneron Pharmaceuticals stock worth more than $15,916,135 as of December 18th. This net worth estimate does not reflect any other assets that Mr. Van Plew may own. Additionally, Mr. Van Plew receives an annual salary of $2,010,000.00 as EVP at Regeneron Pharmaceuticals. Learn More about Daniel P. Van Plew's net worth.

How old is Daniel P. Van Plew?

Mr. Van Plew is currently 51 years old. There are 5 older executives and no younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals is Dr. Leonard S. Schleifer M.D., Ph.D., Co-Founder, President, CEO & Co-Chairman, who is 71 years old. Learn More on Daniel P. Van Plew's age.

What is Daniel P. Van Plew's salary?

As the EVP of Regeneron Pharmaceuticals, Inc., Mr. Van Plew earns $2,010,000.00 per year. There are 2 executives that earn more than Mr. Van Plew. The highest earning executive at Regeneron Pharmaceuticals is Dr. Leonard S. Schleifer M.D., Ph.D., Co-Founder, President, CEO & Co-Chairman, who commands a salary of $8,180,000.00 per year. Learn More on Daniel P. Van Plew's salary.

How do I contact Daniel P. Van Plew?

The corporate mailing address for Mr. Van Plew and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Daniel P. Van Plew's contact information.

Has Daniel P. Van Plew been buying or selling shares of Regeneron Pharmaceuticals?

Daniel P. Van Plew has not been actively trading shares of Regeneron Pharmaceuticals over the course of the past ninety days. Learn More on Daniel P. Van Plew's trading history.

Who are Regeneron Pharmaceuticals' active insiders?

Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Regeneron Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 107,995 shares worth more than $105,556,492.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.

Information on this page was last updated on 8/28/2024.

Daniel P. Van Plew Insider Trading History at Regeneron Pharmaceuticals

See Full Table

Daniel P. Van Plew Buying and Selling Activity at Regeneron Pharmaceuticals

This chart shows Plew Daniel P. Van's buying and selling at Regeneron Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Read More

Today's Range

Now: $740.01
Low: $721.08
High: $744.80

50 Day Range

MA: $839.04
Low: $724.87
High: $1,016.53

2 Week Range

Now: $740.01
Low: $721.08
High: $1,211.20

Volume

978,715 shs

Average Volume

559,383 shs

Market Capitalization

$81.32 billion

P/E Ratio

18.31

Dividend Yield

N/A

Beta

0.08
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits   |   Ad
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
>> Register for the Workshop Now